Objective: To assess the safety and efficacy of on-pump beating heart coronary surgery on organ function, and early and late health outcome as compared with conventional technique. Methods: A total of 81 patients were randomised to (1) coronary surgery with cardiopulmonary bypass (CPB) and cardioplegic arrest (CA) (on-pump with CA, n = 41) or to (2) CPB without CA (on-pump without CA, n = 40). Primary outcomes included serial measurement of interleukins (IL-6, IL-8 and IL-10) for inflammation, troponin I for myocardial injury, protein S100 for cerebral injury and creatinine clearance (CrCl) and urinary N-acetyl-b-D-glucosaminidase (NAG) for renal injury. In-hospital health outcome and 5-year event-free survival were secondary outcomes. Results: Baseline and intra-operative characteristics were similar between groups. A marked release of ILs was observed in both groups, but no significant differences between the groups were found (IL-6 +9%, 95% confidence interval (CI) À15% to +39%, p = 0.49; IL-8 +4%, 95% CI À34% to +63%, p = 0.86; IL-10 À0.1%, 95% CI À19% to +21%, p = 0.93). Troponin I rose in both groups and was on average 34% higher in the on-pump without CA group but this did not reach statistical significance (95% CI À0.4% to +87%, p = 0.08). S100 protein was higher in the on-pump without CA group at 12 h ( p = 0.04) but did not differ at other times ( p = 0.16). The level of CrCl was higher 1 h in the on-pump without CA group (+23%, 95% CI +1% to +50%, p = 0.04), but not thereafter. NAG release was similar in both groups (+1% 95% CI À23% to +33%, p = 0.91). Early and 5-year health outcomes were similar. Conclusions: On-pump without CA coronary surgery does not provide any obvious advantage when compared with the conventional technique of on-pump with CA in elective patients. Both techniques provide a comparable degree of inflammatory activation, myocardial, cerebral and renal injury with similar 5-year event-free survival. #
Introduction
Conventional coronary artery bypass grafting (CABG) improves symptoms and prognosis [1] [2] [3] [4] [5] but is associated with significant in-hospital mortality and morbidity mostly due to the non-physiologic nature of cardiopulmonary bypass (CPB) and cardioplegic arrest (CA) [1] [2] [3] [4] .
Both CPB and CA have the potential to determine inflammatory activation, myocardial, cerebral and renal dysfunction although the independent effects of CPB and CA have not been investigated [1] [2] [3] [4] [5] . CPB-related factors including lower systemic pressures, non-pulsatile blood flow and exposure of blood to artificial surfaces, can lead to subsystem organ injury and activation of inflammatory humoral and cellular responses [1] [2] [3] [4] . Concomitantly, CA-related factors including global cardiac ischaemia have also been associated with myocardial injury [6] , low cardiac output [5] , renal impairment [7] and release of free oxygen radicals and interleukins (ILs) after reperfusion of the ischaemic myocardium [3, 4] .
CPB and CA can both be avoided with off-pump coronary artery bypass (OPCAB) surgery, which we have shown is associated with reduced in-hospital morbidity and costs [6] [7] [8] [9] [10] [11] [12] compared with conventional CABG with CPB and CA, without affecting long-term graft patency rate [12] .
Recently, a novel hybrid procedure of beating heart surgery with the use of CPB to support the systemic circulation but without CA has been used in an increasing number of centres to treat high-risk patients with either poor left ventricular function or recent myocardial infarction [13] [14] [15] [16] [17] . Yet, to date, very little data exist as part of a clinical trial to validate this surgical approach. In this randomised controlled trial, we set to evaluate the surgical technique of on-pump without CA versus conventional surgery by assessing its impact on inflammation, myocardial, cerebral, and renal injury, early health outcome and 5-year event-free survival in elective patients undergoing CABG.
Materials and methods
Between January 2003 and October 2004, 82 patients undergoing elective, multivessel, isolated, primary CABG were randomised to one of two groups: (1) CPB and CA (on-pump with CA) or (2) CPB with coronary grafting performed on the beating heart (on-pump without CA). The trial had local research ethics committee approval and all patients gave written informed consent. Random treatment allocations, stratified by consultant team (two strata), were generated by computer in blocks of unequal length. Allocation details were concealed in sequentially numbered, opaque sealed envelopes. Exclusion criteria were set to minimise potential confounding on the primary end points of inflammatory activation and sub-system organ injury associated with an unbalanced distribution of predisposing baseline risk factors. Exclusion criteria included: a myocardial infarction within the last 7 days; severe left ventricular impairment (ejection fraction (EF) < 30%); symptomatic cerebrovascular disease; renal insufficiency (serum creatinine ! 130 mmol l À1 ); presence of bleeding diathesis, bullous emphysema on CXR, and/or significant chronic obstructive airway disease (forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) < 40%), history of pericarditis, median sternotomy, thoracotomy, chest irradiation or pleurodesis, smoking 1 month prior to surgery, significant peripheral vascular disease and use of aspirin within 4 days prior to surgery.
Management of pre-and postoperative medications
Preoperative medications including b-blockers, diuretics, anti-hypertensives, and calcium channel blockers were routinely omitted on the day of surgery. Angiotensin-converting enzyme (ACE)-inhibitors were withdrawn on the evening before the operation. On the first postoperative day, in accordance with the intensive care unit protocol (heart rate > 55 bpm, systolic blood pressure > 110 mm Hg) b-blockers and anti-hypertensive drugs were restarted.
Primary outcome measures

Inflammatory activation
Inflammatory activation was assessed by measuring serial release of IL-6, -8, and -10. ILs were measured (enzymelinked immunosorbent assay (ELISA), R and D Systems, Europe Ltd.) preoperatively and at 1, 4, 12 and 24 h following surgery.
Myocardial injury
Myocardial injury was assessed by measuring serial release of cardiac troponin I preoperatively and at 1, 4, 12, 24 and 48 h, postoperatively.
Cerebral injury
Neurological injury was assessed by measuring serial release of serum S100 protein preoperatively, 1, 4, 12 and 24 h postoperatively. The S100 analysis was performed using the CanAg S100 Enzyme Immunometric assay (EIA) kit. The CanAg S100 EIA is a solid-phase, two-step, noncompetitive immunoassay based on two mouse monoclonal antibodies specific for two different epitopes expressed in S100B. The assay determines both S100A1B and S100BB without cross-reactivity with other forms of S100.
Renal injury
Urinary N-acetyl-b-D-glucosaminidase (NAG) and urinary creatinine were measured from urine samples collected immediately before, 1, 24 and 48 h after CPB. Spectrophotometric assay for NAG activity was performed. This involved gel filtration of the urine samples to separate inhibitors of the enzyme followed by enzymatic hydrolysis of p-nitrophenylate-N-acetyl-b-D-glucosaminidase at pH 4.4. The liberated p-nitrophenylate was then measured spectrophotometrically. Creatinine clearance (CrCl) was used to assess the glomerular filtration rate. Urine samples provided urinary creatinine concentration and urinary flow values, and along with plasma creatinine concentration enabled us to calculate the CrCl using the following formula:
Creatinine clearance ðCrClÞ ¼ urine creatinine concentration Â urine flow rate plasma creatinine concentration
Secondary outcome measures
These included in-hospital clinical outcome and 5-year event-free survival. Deaths post-hospital discharge were obtained by linking with the National Health Service (NHS) Strategic Tracing Service (NSTS). Cardiac-related events (heart attack, percutaneous or surgical revascularisation and heart failure) post-discharge was ascertained from annual follow-up questionnaires sent to both patients and their family practitioners.
Anaesthetic techniques
A standard anaesthetic technique was used throughout, as previously reported [9, 10] . Briefly, fentanyl 20-35 mg kg À1 and pancuronium 0.15 mg kg À1 was used in all cases along with isoflurane or propofol prebypass. Propofol 3 mg kg À1 h À1 infusion was used during bypass. An individualised calculation of heparin and protamine dose was carried out using the R x D x system (International Techidyne Corp., NJ, USA) to minimise protamine-induced complement activation. The target activated clotting time (ACT) was 480 s throughout surgery.
Cardiopulmonary bypass and surgical technique
CPB was instituted using ascending aortic and two-stage venous cannulation. A Cobe roller pump, hollow-fibre membrane oxygenator (Monolyth, Sorin Biomedica Cardio S.R.L., Saluggia (Vercelli), Italy) was used. The extra corporeal circuit was primed with 1000 ml of Hartmann's solution, 500 ml of Gelofusine and 7 ml of 10% calcium gluconate. Non-pulsatile flow was used and systemic temperature maintained between 34 and 36 8C. An arterial line filter was employed in all cases (40 mm, Pall Filter). Sodium nitroprusside, noradrenaline and phenylephrine were used as required to maintain the target mean arterial pressures (MAP). In both groups, the target flow rate was 2.4 l m À2 min
À1
.
2.5.1. On-pump with CA group Myocardial protection was achieved using intermittent antegrade warm blood cardioplegia as previously reported [9, 10] . Proximal anastomoses were performed following aortic cross-clamp removal using a partial occlusion aortic clamp. The target mean arterial pressure (MAP) was kept as per routine, between 60 and 70 mm Hg.
On-pump without CA group
On-pump without CA surgery is shown in Fig. 1 . Having established CPB for heart positioning and stabilisation, we used our OPCAB technique previously described [9, 10] . An intracoronary shunt was used for all coronary anastomoses. Visualisation was enhanced by using a surgical blowerhumidifier. The target MAP was purposely kept higher, at between 70 and 80 mm Hg, to optimise coronary perfusion during beating heart coronary grafting.
Postoperative management
This was as reported previously [9, 10] . Briefly, following surgery, lungs were ventilated with 60% oxygen using volumecontrolled ventilation and a tidal volume of 10 ml kg À1 with 5 cm H 2 O of positive end-expiratory pressure (PEEP). PaO 2 and PaCO 2 were maintained between 80 and 100 mm Hg and between 35 and 40 mm Hg, respectively. Forced air warming was used. Patients were extubated as soon as they met the following criteria: haemodynamic stability, no excessive bleeding (<80 ml h À1 ), normothermia and consciousness with pain control. Potassium and magnesium deficiency was promptly treated as necessary to maintain electrolyte balance within the normal range.
Monitoring and definitions
Heart rate and rhythm were continuously monitored and displayed on a screen with an automated arrhythmia detector during the first 72 h, postoperatively. Electrocardiography (ECG) recordings were performed serially at baseline, 2 h, 24 h and then daily thereafter until discharge.
Intra-operative and postoperative data, including complications and adverse events, were collected using purposedesigned data collection forms.
Clinical diagnostic criteria for perioperative myocardial infarction (MI) were new Q waves of greater than 0.04 ms, and/or a reduction in R waves greater than 25% in at least two leads.
Chest infection was defined as the presence of purulent sputum associated with fever and requiring antibiotic therapy according to positive sputum culture.
Study size
The target sample size was set at 80 patients. In previous studies [6] [7] [8] [9] , markers of cerebral, renal and myocardial injury and inflammatory activation have been shown to change as much as 10-fold during the first 24-48 h postoperatively, and changes in clinical measures are observed when large changes in biochemical markers occur. The target sample size was chosen in this context; small differences in the mean levels of markers between groups were thought unlikely to be associated with important clinical benefits for patients. The trial had 90% power to detect a standardised difference !0.83 at a 5% significance level (two-tailed).
Statistical analysis
The trial was analysed by intention to treat. Continuous measurements are summarised as a mean and standard deviation or median and interquartile range (IQR), if skewed. Categorical data are reported as number and percentage. All outcome analyses were adjusted for consultant team and baseline measure where appropriate. Continuous outcome measurements were compared using regression analysis and effect sizes are expressed as a mean difference or hazard ratio (time to event measures). Categorical outcomes were compared using logistic regression and effect sizes are reported as odds ratios. Outcomes with fewer than 10 events were not subject to statistical analysis.
Biochemical markers were compared using mixed model regression analysis. A number of models describing the correlation structure of the repeated measures were tested and the one with the lowest value of the Schwarz's Bayesian information statistic was chosen in each case. Logarithmic transformations were applied to all markers due to the skewed nature of their distribution. Interactions of treatment with time were assessed using the F-test and, if statistically significant at the 5% level, treatment differences are reported separately for each time point; otherwise, an overall effect is reported. Results for the markers are reported as geometric means and as a ratio of means. All treatment effect estimates are reported with 95% confidence intervals. Surviving patients, free of cardiac-related events post-discharge were censored at the date of their last questionnaire response. Six patients were excluded as no follow-up questionnaire data had been returned.
Data analysis was performed using STATA, version 9.2 (Stata Corporation, College Station, TX, USA). The regression models for the biochemical markers were fitted using SAS, version 8.2 (SAS Institute, Cary, NC, USA). The results of the trial are reported in accordance with the checklist of the Consolidated Standards of Reporting Trials (CONSORT) statement [18] .
Results
One of the 82 patients randomised was subsequently found to be ineligible leaving 81 patients in the trial; 40 were allocated to on-pump without CA and 41 to on-pump with CA (Fig. 2) . One patient randomised to on-pump without CA was converted to on-pump with CA because of technical difficulty. Baseline and intra-operative characteristics (over-
. Inflammatory activation
All the inflammatory markers were significantly raised after surgery in both groups compared to baseline measures (Table 3 ), but no differences between groups were found (IL-6 +9%, 95% CI À15% to +39%, p = 0.49; IL-8 +4%, 95% CI À34% to +63%, p = 0.86; IL-10 À0.1%, 95% CI À19% to +21%, p = 0.93) (Fig. 3(A)-(C) ). No statistically significant interactions between treatment and time were found ( p ! 013).
Myocardial injury
Troponin I release rose significantly in both groups and was, on average, 34% higher in the on-pump without CA group (Fig. 3(D) ), but the difference was not statistically significant at the 5% level (95% CI À0.4% to +87%, p = 0.08).
Cerebral injury
Serum S100 protein rose significantly in both groups and was higher in the on-pump without CA group at 12 h: +35%, 95% CI +1% to +82%, p = 0.04, but was similar at other times p ! 0.16 ( Fig. 4(A) ).
Renal injury
Markers of renal injury rose significantly in both groups. Serial measurements of NAG, a marker of tubular injury, revealed no difference between the two groups. NAG: +1% 95% CI À23% to +33%, p = 0.91 (Fig. 4(B) ). Glomerular function measured by CrCl was higher 1 h after surgery in the on-pump without CA group (+23%, 95% CI +1% to +50%, p = 0.04), but not thereafter (Fig. 4(C) ). No difference was observed in creatinine:NAG ratio between groups (Fig. 4(D) ).
[ ( F i g . _ 2 ) T D $ F I G ] Results of biochemical markers for cerebral and renal function are tabulated in Table 3 .
Secondary outcomes
In-hospital outcome
There were no in-hospital deaths. The mean duration of CPB was, on average 8.5 min longer in the on-pump without CA group ( p = 0.064). In the on-pump with CA group, the median duration of CA was 36 min (IQR 29-40 min). The mean number of grafts was 2.9 in both groups. Hospital morbidity outcomes were similar in the two groups (Table 2) .
Five-year health outcome
Three patients died within 5 years (all in the on-pump with CA group). Of the surviving patients, five experienced cardiac-related events (two in the on-pump with CA group, three in the on-pump without CA group); two patients had an MI, one of whom required revascularisation; two further patients were also revascularised and one patient suffered congestive heart failure. A Cox's proportional hazards model of event-free survival suggests the event-free survival rate is similar in the two groups; hazard ratio 0.62, 95% CI (0.15, 2.59) for on-pump without CA versus on-pump with CA group, adjusting for consultant team (Fig. 5 ).
Discussion
On-pump without CA coronary surgery has been used by several centres to treat high-risk patients with either poor left ventricular function or recent MI [13] [14] [15] [16] [17] with a view to minimise myocardial ischaemia associated with cardioplegic arrest.
Our trial suggests that the use of on-pump without CA coronary surgery in elective patients is not associated with any obvious advantages when compared with conventional surgery with CPB and CA. In particular, the degree of inflammatory activation and myocardial injury was comparable between groups, while the transient cerebral and renal dysfunction associated with on-pump without CA was followed by prompt recovery.
The secondary outcome of our trial appears to suggest that on-pump without CA surgery might be safe and effective with in-hospital health outcome and 5-year free event survival comparable to conventional surgery. Nevertheless, the trial was not powered to detect meaningful clinical differences.
The degree of inflammatory activation and myocardial injury was significant but comparable between groups. Because cardioplegic arrest was not used in the on-pump without CA group, it could be argued that the observed changes in inflammation and myocardial injury were due to CPB and surgical trauma alone. This is a novel finding as most of the available evidence arises from studies in which CPB, CA and surgical trauma were concomitantly used [1] [2] [3] [4] 19, 20] . Of interest, this finding is in keeping with the study by Rastan et al. [14] , who assessed the occurrence of myocardial injury in 40 elective patients randomised to either OPCAB or onpump without CA surgery. They showed that on-pump without CA surgery led to marked myocardial injury with a significantly higher release of creatinine kinase-MB (CK-MB) and Tn I up to 4 h, postoperatively when compared with OPCAB surgery.
On the other end, it could be argued that the similar degree of inflammatory activation and myocardial injury observed in the two groups of our trial might be due to an intrinsic capacity of the myocardium to tolerate up to 35 min of cardioplegic ischaemia in the conventional group (the median CA time in the on-pump with CA group was 36 min) with no further inflammatory activation and myocardial injury than that associated with CPB and surgical trauma alone observed in the on-pump without CA group. In the onpump with CA group, we used intermittent antegrade warm blood cardioplegia delivered over the course of 2 min and repeated after each anastomosis. Because the mean number of graft was 2.9 per patient, we had effectively a sequence of three cycles of 2 min of warm cardioplegia interspersed by about 10 min of ischaemia (average anastomotic time). We postulate that this specific sequence of events might have effectively preconditioned the heart eliciting this endogen- ous protection [21] . It is likely, however, that CA time longer than 35 min might have been associated with more pronounced inflammation and myocardial injury. Other investigators have suggested that the duration of CA is the only independent predictor of postoperative IL-6 release and that the levels of IL-6 and IL-8 are higher in patients with longer duration of myocardial ischaemia [19] . Of interest, in the on-pump without CA group, there was a 34% higher release of troponin I compared with conventional technique although this did not reach statistical significance. However, this difference cannot be related to variability in the extent of coronary disease as double-and triple-vessel coronary disease was distributed equally between groups. While on-pump without CA surgery was associated with an increase in serum S100 protein, a marker of cerebral injury [9] at 12 h and in CrCl, indicating impaired glomerular filtration [7] at 1 h post surgery when compared with onpump with CA, these effects were transient; at other time points, the results were similar in the two groups. Studies have shown that high levels of S100 and cerebral dysfunction after cardiac surgery may be cytokine mediated [22] , but the bulk of the evidence points towards micro-emboli as the major cause of post-cardiac surgery cerebral dysfunction [9, 23] . In a study comparing on-pump versus off-pump coronary surgery, we demonstrated that elevated S100 was strongly associated with retinal and cerebral micro-embolisation [9] . Cerebral embolisation is known to occur during CPB, especially during aortic cannulation, aortic clamping and clamp removal [9, 24] . Avoidance of cross-clamp application therefore would have been expected to lower embolic load and S100 levels in the on-pump without CA group due to the reduction of aortic manipulation. Yet, in this group, there was a higher release of S100 protein at 12 h post-CPB suggesting that aortic cannulation and site-bite clamping might be more detrimental that aortic cross-clamping itself.
Apart from CrCl being higher 1 h after surgery in the onpump without CA group, there were no significant differences between the two groups in terms of CrCl, NAG and NAG/CrCl ratio. A possible explanation is that CPB is the main determinant of renal dysfunction as this factor was common to both groups in this trial. Studies have shown that avoidance of CPB in elective patients with normal preoperative renal function leads to a significantly lower release of markers of renal injury [7] . Furthermore, when renal function is impaired preoperatively, avoidance of CPB may have a clinical protective effect by reducing the incidence of renal failure [25] .
The levels of markers of inflammation, myocardial, cerebral and renal injury observed in both groups of the present trial are higher than those observed in the OPCAB group of our previous studies [6] [7] [8] [9] . Taken together, these studies suggest that CPB might be the major determinant of the observed changes.
Our trial also suggests that on-pump without CA surgery might offer early and 5-year clinical outcome comparable to the outcome observed following conventional surgery. Note: Not all percentages sum to exactly 100% due to rounding. a Effect sizes are quantified for all continuous variables and for categorical ones with more than 10 events across the population.
For continuous variables where the median and IQR are reported, the effect size is the difference in the medians between the two groups.
For continuous variables where the mean and SD are reported, the effect size effect is the difference in means.
For the variables ITU stay, and Hospital stay the effect size effect is the hazard ratio. For categorical variables, the effect size is the odds ratio. However, we would like to point out that (1) the outcome of our trial applies only to elective patients selected according to the proposed criteria, and that (2) health outcome was only a secondary outcome of our trial, which was not powered to detect meaningful clinical differences. Despite the lack of appropriate validation, several groups have used on-pump without CA over recent years in high-risk patients. Perrault et al. [15] were the first to report a mix of 37 consecutive patients at high-risk due to different causes (poor LV, ongoing MI or advanced age). They concluded that this technique may be an acceptable trade-off, but no control group was available. More recently, Izumi et al. [16] and Miyahara et al. [17] have reported two small series of 31 and 61 patients, respectively, presenting with acute MI and undergoing emergency surgery, performed with conventional CABG in the earlier part of their series or with on-pump without CA in the later part. Both groups report better clinical outcome associated with the use of on-pump beating heart surgery. However, these observational studies have major limitations in design.
Recently, Pegg et al., in a small trial of 50 patients with impaired LV function, compared on-pump without CA versus on-pump with CA [13] . Patients were assessed with cardiac magnetic resonance imaging and biochemical markers of myocardial injury including troponin I. The authors reported a higher irreversible myocardial injury in the on-pump without CA group and suggested that the most likely mechanism is inadequate coronary perfusion to distal myocardial territories possibly due to the use of intracoronary shunts. By contrast, our larger trial shows no statistically significant difference in myocardial injury. This discrepancy could be due to differences in sample size, patient exclusion criteria, distribution of coronary disease and perfusion techniques. In particular, we might have achieved a better myocardial perfusion during grafting in the on-pump without CA group as we used a CPB MAP between 70 and 80 mm Hg, which is higher than the 50-60 mm Hg used in the trial by Pegg et al. [13] .
In conclusion, on-pump without CA coronary surgery does not provide any obvious advantage in terms of inflammatory activation, myocardial, cerebral and renal injury when compared with the conventional technique of on-pump with CA in elective patients. Early and 5-year clinical outcome also seems to be similar between groups, but this outcome should be confirmed with a larger study. Based on the outcome of this trial the use of on-pump without CA instead of conventional surgery with CPB and CA is not justified in elective patients.
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